Business Context and Reporting Period
Company: Curis, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 5, 2009
Principal Executive Offices: Cambridge, MA
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on executive compensation decisions.
Material Changes and Events
Executive Incentive Plan Decision
The Compensation Committee determined not to make payments under the 2008 cash incentive plan for executive officers, despite specific goals being met. This decision was made explicitly to preserve cash.
- Plan Structure: Four equally-weighted categories (CUDC-101 development, nomination of candidates, collaborations, financial performance).
- Performance Achieved:
- Development goals (CUDC-101): Threshold level achieved.
- Nomination of candidates: Target level achieved.
- Collaborations: Not achieved at a payable level.
- Financial performance: Threshold level achieved.
- Forfeited Earned Amounts:
- Daniel R. Passeri: $100,000
- Michael P. Gray: $52,500
- Changgeng Qian: $37,500
- Mark W. Noel: $15,750
Director and Officer Compensation
The Board of Directors determined to leave cash compensation for non-employee directors for 2009 unchanged from 2008 rates. Similarly, cash compensation for named executive officers remains unchanged from rates disclosed in the Form 10-Q for the quarter ended September 30, 2008.
Guidance, Outlook, and Risks
Management Commentary: The primary driver for the cancellation of earned incentive payments was the need to preserve cash, indicating liquidity constraints or a strategic shift toward cash conservation during the reporting period.
Risks/Contingencies: The filing highlights the company's sensitivity to cash flow management, as evidenced by the decision to withhold earned executive compensation.
Investor Verification Checklist
- Verify the company's current cash position and liquidity runway in the most recent Form 10-Q or 10-K.
- Confirm the status of the CUDC-101 clinical trial enrollment and IND filing mentioned in the development goals.
- Review the impact of the $205,750 in withheld executive compensation on the company's cash flow statement for the period.
- Assess whether the "Threshold" achievement of financial performance objectives indicates broader operational challenges.